Full length deletion of ANRIL was associated with cutaneous melanoma [47] and the CHD and AgP high-risk haplotype, overlapping exons 13–19 of ANRIL, is associated with diseases that also share a phenotype of abnormal cell proliferation. Here, CDKN2B-AS1 is linked to cutaneous melanoma.